ArticleScientific reports2025
Amino acid metabolites as potential circulating biomarkers for sarcopenia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating PBX1 and age-related sarcopenia phenotypes: metabolic mediation analyses in a community-based study.European geriatric medicine · 2026Article
- Metabolomic biomarker differences of sarcopenia in older patients with sepsis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sarcopenia, characterized by the loss of muscle mass and strength, is a multifactorial disorder, including metabolic disturbance. Plasma amino acids (AAs) regulate muscle protein synthesis and breakdown. This study evaluated plasma AA metabolites as potential biomarkers for sarcopenia using metabolomic analysis. We assessed 31 AA metabo lites in an age-matched discovery cohort (72 men, 36 women with sarcopenia; 72 and 36 controls) and a validation cohort (36 men, 46 women with sarcopenia; 128 and 112 controls). In discovery cohort, isoleucine (Ile), leucine (Leu), valine (Val), methionine (Met), phenylalanine (Phe), tryptophan (Trp), alpha-aminoadipic acid (alpha-AAA), glutamate (Glu), and methionine sulfoxide (MetO) were lower in men with sarcopenia, while Glu was lower in women (p < 0.05). Leu in men and Glu in both sexes were associated with skeletal muscle index. A regression model combining Leu and Glu in men and Glu in women yielded an AA score. Adding the AA score to hand grip strength improved the area under the receiver-operating characteristic curve in men (0.646 to 0.767, p = 0.003; 0.563 to 0.767, p = 0.002) and in women (0.486 to 0.728, p < 0.001; 0.576 to 0.680, p = 0.018). Leu in men and Glu in both sexes, reflecting low muscle mass, are potential circulating biomarkers for sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.